Longitudinal analysis at pre- and post-flare of T peripheral helper and T follicular helper subsets in patients with systemic lupus erythematosus.

Flare Systemic lupus erythematosus Tph cells circulating Tfh cells

Journal

Immunology letters
ISSN: 1879-0542
Titre abrégé: Immunol Lett
Pays: Netherlands
ID NLM: 7910006

Informations de publication

Date de publication:
03 Aug 2024
Historique:
received: 24 04 2024
revised: 27 06 2024
accepted: 02 08 2024
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 5 8 2024
Statut: aheadofprint

Résumé

We focused to analyze the time-course changes at pre- and post-flare of T peripheral helper (Tph) cells and circulating T follicular helper (Tfh) cells in the blood of patients with systemic lupus erythematosus (SLE) with lupus low disease activity state (LLDAS) before flare. This study included inactive (n=29) and active (n=55) patients with SLE. Tph subsets, Tfh subsets, CD11c Active SLE patients exhibited the increased frequency of Tph1, Tph2, Tfh1, and Tfh2 subsets when compared to inactive patients, but no clear changes in the other subsets. During the treatment with medications, Tph1, Tph2, and Tfh2 subsets were significantly reduced along with disease activity and Tph1 and Tph2 subsets were positively correlated with SLE disease activity index (SLEDAI). The time course analysis of patients at pre- and post-flare revealed that in the patients at LLDAS before flare, Tph subsets and Tfh subsets were relatively low levels. At the flare, Tph cells, particularly Tph1 and Tph2 subsets, were increased and correlated with SLEDAI. Furthermore, the blood levels of IFN-α2a, IFN-γ, and IFN-λ1 were low in the patients with LLDAS before flare but these IFNs, particularly IFN-λ1, were increased along with flare. Increased frequency of Tph1 and Tph2 subsets and elevated levels of serum IFN-λ1 are presumably critical for triggering of flare in SLE.

Identifiants

pubmed: 39103125
pii: S0165-2478(24)00079-8
doi: 10.1016/j.imlet.2024.106905
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106905

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mitsuhiro Akiyama: Asahikasei Pharma Corp., Astellas Pharma Inc., Boehringer Ingelheim Co., Ltd., Eli Lilly Japan KK., Pfizer Japan Inc., and UCB Japan Co., Ltd. Tsutomu Takeuchi: AbbVie GK, Bristol-Myers KK, Chugai Pharmaceutical Co., Ltd. Noriyasu Seki, Hideto Tsujimoto, Shuhei Tanemura, Kunio Sugahara, a nd Kenji Chiba : Mitsubishi Tanabe Pharma Corporation employee

Auteurs

Noriyasu Seki (N)

Innovative Research division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Hideto Tsujimoto (H)

Innovative Research division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Shuhei Tanemura (S)

Innovative Research division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Jun Kikuchi (J)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Shuntaro Saito (S)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Kunio Sugahara (K)

Innovative Research division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Keiko Yoshimoto (K)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Mitsuhiro Akiyama (M)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Tsutomu Takeuchi (T)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Saitama Medical University, Iruma-gun, Saitama, Japan.

Kenji Chiba (K)

Innovative Research division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: Chiba.Kenji@mk.mt-pharma.co.jp.

Yuko Kaneko (Y)

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Classifications MeSH